Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | NAMPT | P43490 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 2/20 | 0.31 |
| ▸ | GAA | P10253 | 2/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | GFER | P55789 | 1/20 | 0.31 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1690524 | 1.00 | EPHX1 (0.38) | EPHX1MAPTALDH1A1NPC1MEN1 | |
| SCHEMBL14942466 | 1.00 | EPHX1 (0.38) | EPHX1MAPTALDH1A1NPC1MEN1 | |
| SCHEMBL14877965 | 0.92 | EPHX1 (0.34) | EPHX1MAPTALDH1A1NPC1KDM4E | |
| SCHEMBL2617044 | 0.87 | MAPT (0.38) | MAPTALDH1A1NAMPTHTTPOLB | |
| SCHEMBL13165512 | 0.87 | MAPT (0.38) | MAPTALDH1A1NAMPTHTTPOLB | |
| SCHEMBL13165462 | 0.87 | MAPT (0.38) | MAPTALDH1A1NAMPTHTTPOLB | |
| SCHEMBL76462 | 0.87 | — | — | |
| Ammonia Solution, Strong SCHEMBL29124228 | 0.84 | — | — | |
| SCHEMBL31461753 | 0.84 | — | — | |
| SCHEMBL27641897 | 0.84 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 174 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113286776-B | Bicyclic and tricyclic compounds useful as fragrance chemicals | 巴斯夫欧洲公司 | 2024-07-26 | — | — | CN | disclosed |
| US-20240207267-A1 | (R)-Glutarimide CRBN Ligands and Methods of Use | BEIGENE SWITZERLAND GMBH (CH) | 2024-06-27 | — | — | US | disclosed |
| US-20240025902-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF EGFR AND RELATED METHODS OF USE | BEONE MEDICINES I GMBH (CH) | 2024-01-25 | — | — | US | disclosed |
| WO-2023223639-A1 | POLYMERIZABLE COMPOUND, POLYMERIZABLE COMPOSITION, OPTICAL FILM, AND DISPLAY APPARATUS | 住友化学株式会社 | 2023-11-23 | — | — | WO | disclosed |
| US-RE49686-E1 | Nitrogen-containing heterocyclic compound and use of same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-10-10 | — | — | US | disclosed |
| US-20230265116-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEONE MEDICINES I GMBH (CH) | 2023-08-24 | — | — | US | disclosed |
| CN-112279744-B | Method for the conversion of biologically derived mevalonate | 维索利斯有限公司 | 2023-08-15 | — | — | CN | disclosed |
| US-20230248834-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEONE MEDICINES I GMBH (CH) | 2023-08-10 | — | — | US | disclosed |
| US-20230248834-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEONE MEDICINES I GMBH (CH) | 2023-08-10 | — | — | US | disclosed |
| WO-2023097038-A1 | CLEAVABLE RADIOLIGANDS FOR TARGETING CELL SURFACE RECEPTORS AND USES THEREOF | FULL-LIFE TECHNOLOGIES U.S. INC. (US) | 2023-06-01 | — | — | WO | disclosed |
| US-20090163549-A1 | Pharmaceutical Composition Comprising an Amide Derivative | SHIONOGI & CO., LTD. (JP) | 2009-06-25 | — | — | US | disclosed |
| US-20090137736-A1 | Accelerants for the Modification of Non-Natural Amino Acids and Non-Natural Amino Acid Polypeptides | AMBRX, INC. (US) | 2009-05-28 | — | — | US | disclosed |
| WO-2009061596-A1 | COMPOUNDS FOR INHIBITING KSP KINESIN ACTIVITY | SCHERING CORPORATION (US) | 2009-05-14 | — | — | WO | disclosed |
| US-20090042900-A1 | 2,4-DIAMINOQUINAZOLINES FOR SPINAL MUSCULAR ATROPHY | DECODE CHEMISTRY, INC. (US) | 2009-02-12 | — | — | US | disclosed |
| US-7402608-B2 | Compounds and methods for the treatment or prevention of Flavivirus infections | VIROCHEM PHARMA INC. (CA) | 2008-07-22 | — | — | US | disclosed |
| US-7332488-B2 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2008-02-19 | — | — | US | disclosed |
| US-7273875-B2 | Naphthyridine derivatives, their preparation and their use as phosphodiesterase isoenzyme 4 (PDE4) inhibitors | NOVARTIS AG (CH) | 2007-09-25 | — | — | US | disclosed |
| EP-1835343-A1 | Positive resist composition and pattern formation method using the positive resist composition | FUJIFILM Corporation (JP) | 2007-09-19 | — | — | EP | disclosed |
| WO-2007026959-A2 | DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZ0 [B] THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-03-08 | — | — | WO | disclosed |
| US-4187251-A | DEODORIZING, ALKYLCYCLOHEXYL ALKYL KETONES | SCHLEPPNIK ALFRED A | 1980-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137736-A1 | Accelerants for the Modification of Non-Natural Amino Acids and Non-Natural Amino Acid Polypeptides | DNPEP, DAO, AADAT | EPHX1 4306/4885MAPT 3691/4885ALDH1A1 2901/4885 |
| US-20230265116-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | EGFR, CBL, ERBB2 | EPHX1 2466/4885MAPT 3181/4885ALDH1A1 3281/4885 |
| US-20090163549-A1 | Pharmaceutical Composition Comprising an Amide Derivative | TRPV1, TRPA1, TRPV2 | EPHX1 2423/4885MAPT 2256/4885ALDH1A1 1926/4885 |
| US-20240207267-A1 | (R)-Glutarimide CRBN Ligands and Methods of Use | CRBN, CDR2, CRKL | EPHX1 3672/4885MAPT 2667/4885ALDH1A1 2445/4885 |
| US-20240025902-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF EGFR AND RELATED METHODS OF USE | EGFR, ERBB2, CBL | EPHX1 2515/4885MAPT 3520/4885ALDH1A1 3514/4885 |
| US-20230248834-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | EGFR, CBL, ERBB2 | EPHX1 2466/4885MAPT 3181/4885ALDH1A1 3281/4885 |
| US-20090042900-A1 | 2,4-DIAMINOQUINAZOLINES FOR SPINAL MUSCULAR ATROPHY | SMN1; SMN2, MUSK, MYT1 | EPHX1 4358/4885MAPT 715/4885ALDH1A1 1308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.